FLUVOXAMINE 100 MG
FLUVOXAMINE MALEATE : 100 MG · DIN 02231193 · APOTEX INC
Health Canada status: APPROVED
What is FLUVOXAMINE?
FLUVOXAMINE 100 MG contains FLUVOXAMINE MALEATE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02231193, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 20-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02231193 |
|---|---|
| Brand name | FLUVOXAMINE |
| Generic / active ingredient | FLUVOXAMINE MALEATE : 100 MG |
| Manufacturer | APOTEX INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB08 FLUVOXAMINE |
| AHFS class | 28:16.04.20 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 20-Mar-2020 |
What can be used instead?
Other Canadian products sharing ATC code N06AB08 FLUVOXAMINE. 6 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FLUVOXAMINE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02231330 |
| APO-FLUVOXAMINE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02231329 |
| LUVOX | 100 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 01919369 |
| LUVOX | 50 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 01919342 |
| TEVA-FLUVOXAMINE | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02255537 |
| TEVA-FLUVOXAMINE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02255529 |
| AVA-FLUVOXAMINE | 100 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363771 |
| AVA-FLUVOXAMINE | 50 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363763 |
| BCI FLUVOXAMINE TABLETS | 100.0 MG | TABLET | BAKER CUMMINS INC | CANCELLED POST MARKET | DIN 02257688 |
| BCI FLUVOXAMINE TABLETS | 50.0 MG | TABLET | BAKER CUMMINS INC | CANCELLED POST MARKET | DIN 02257661 |
Who else supplies FLUVOXAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUVOXAMINE appears in 127 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.